CG Oncology (CGON) Common Equity (2023 - 2026)

CG Oncology has reported Common Equity for 4 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 54.92% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 54.92% YoY), and the FY2025 full-year result was $752.6 million, up 2.62% from the prior year.
• Common Equity for Q1 2026 stood at $1.1 billion, up from $752.6 million in the prior quarter.
• The five-year high for Common Equity was $1.1 billion in Q1 2026, with the low at -$123.1 million in Q4 2023.
• Historically, Common Equity has averaged $452.6 million across 4 years, with a median of $568.9 million in 2024.
• Annual changes were most pronounced in 2024 — Common Equity jumped 760.66% — and 2025, when it gained 2.62%.
• CG Oncology's Common Equity stood at -$123.1 million in 2023, then soared by 695.76% to $733.4 million in 2024, then rose by 2.62% to $752.6 million in 2025, then soared by 45.07% to $1.1 billion in 2026.
• The last three Common Equity figures came in at $1.1 billion (Q1 2026), $752.6 million (Q4 2025), and $687.6 million (Q3 2025), per Business Quant data.